注意转化差距：导管原位癌的临床前模型 - Suppr

Suppr

超能文献

MIND the translational gap: Preclinical models of ductal carcinoma in situ.

作者信息

Hutten Stefan J, Jonkers Jos

机构信息

Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.

出版信息

Clin Transl Med. 2023 Aug;13(8):e1376. doi: 10.1002/ctm2.1376.

DOI:10.1002/ctm2.1376

PMID:37620984

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10449811/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67da/10449811/6f39c43b96a8/CTM2-13-e1376-g002.jpg

相似文献

MIND the translational gap: Preclinical models of ductal carcinoma in situ.注意转化差距：导管原位癌的临床前模型

Clin Transl Med. 2023 Aug;13(8):e1376. doi: 10.1002/ctm2.1376.

Intraductal proliferations of the breast: a review of histologic criteria for atypical intraductal hyperplasia and ductal carcinoma in situ, including apocrine and papillary lesions.乳腺导管内增生：非典型导管内增生及导管原位癌组织学标准综述，包括大汗腺及乳头状病变

Ann Diagn Pathol. 1998 Apr;2(2):135-45. doi: 10.1016/s1092-9134(98)80051-8.

Intraductal delivery of nanocarriers for ductal carcinoma treatment: a strategy to enhance localized delivery.用于导管癌治疗的纳米载体导管内递送：一种增强局部递送的策略。

Nanomedicine (Lond). 2022 Oct;17(24):1871-1889. doi: 10.2217/nnm-2022-0234. Epub 2023 Jan 25.

HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.通过荧光原位杂交和免疫组织化学检测纯导管原位癌以及浸润性导管癌的导管内和浸润成分中的HER2状态。

Histopathology. 2006 May;48(6):702-7. doi: 10.1111/j.1365-2559.2006.02403.x.

Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.保乳手术及乳腺导管原位癌（导管内癌）根治性放疗后局部复发的挽救性治疗。

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):3-9. doi: 10.1016/0360-3016(94)90512-6.

Pleomorphic lobular carcinoma in situ composed of signet ring cells mimicking cribriform ductal carcinoma in situ.

Breast J. 2020 Oct;26(10):2050-2051. doi: 10.1111/tbj.13935. Epub 2020 Jun 26.

A practical approach to breast ductal carcinoma in situ and tumors with an extensive intraductal component.乳腺导管原位癌及具有广泛导管内成分肿瘤的实用诊疗方法

Pathology. 1994 Apr;26(2):90-3. doi: 10.1080/00313029400169271.

[Ductal carcinoma in situ].导管原位癌

Harefuah. 2004 Mar;143(3):227-31, 244.

Not all ductal carcinoma in situ is created equal: can we avoid surgery for low-risk ductal carcinoma in situ?并非所有导管原位癌都相同：我们能否避免对低风险导管原位癌进行手术？

ANZ J Surg. 2016 Nov;86(11):859-860. doi: 10.1111/ans.13659.

Ductal carcinoma in situ (intraductal carcinoma) of the breast.乳腺导管原位癌（导管内癌）

N Engl J Med. 1988 Apr 7;318(14):898-903. doi: 10.1056/NEJM198804073181406.

引用本文的文献

PCSK5 is a recessive hypomorph exclusive to MCF10DCIS.com cells.PCSK5是MCF10DCIS.com细胞所特有的隐性亚效等位基因。

bioRxiv. 2025 Mar 7:2025.03.03.641323. doi: 10.1101/2025.03.03.641323.

本文引用的文献

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.患者源性原位导管癌小鼠原位异种移植活体生物库鉴定浸润进展的风险因素。

Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27.

Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.乳腺导管原位癌的分子分类和临床结局的生物标志物：TBCRC 038 和 RAHBT 队列的分析。

Cancer Cell. 2022 Dec 12;40(12):1521-1536.e7. doi: 10.1016/j.ccell.2022.10.021. Epub 2022 Nov 17.

Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study.基底样乳腺癌原位至浸润性进展的分子特征：一项整合的小鼠模型和人导管原位癌研究

NPJ Breast Cancer. 2022 Jul 18;8(1):83. doi: 10.1038/s41523-022-00450-w.

Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.未切除的筛检性导管原位癌：Forget-Me-Not 2 研究中 311 名女性的结局。

Breast. 2022 Feb;61:145-155. doi: 10.1016/j.breast.2022.01.001. Epub 2022 Jan 4.

Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy.鼠乳腺内（MIND）：一种用于研究 DCIS 恶性肿瘤潜在机制的体内模型。

J Pathol. 2022 Feb;256(2):186-201. doi: 10.1002/path.5820. Epub 2021 Dec 13.

Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma to Invasive Ductal Carcinoma.非低级别导管癌进展为浸润性导管癌的全外显子组测序分析。

Clin Cancer Res. 2020 Jul 15;26(14):3682-3693. doi: 10.1158/1078-0432.CCR-19-2563. Epub 2020 Mar 27.

Genomic landscape of ductal carcinoma in situ and association with progression.导管原位癌的基因组景观及其与进展的关联。

Breast Cancer Res Treat. 2019 Nov;178(2):307-316. doi: 10.1007/s10549-019-05401-x. Epub 2019 Aug 17.

Ductal carcinoma in situ: to treat or not to treat, that is the question.导管原位癌：治疗还是不治疗，这是个问题。

Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6. Epub 2019 Jul 9.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.在植入肿瘤异种移植物的造血人源化小鼠中对抗 PD-1 单药和联合免疫治疗的免疫反应特征。

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.未切除的导管原位癌发展为浸润性癌的危险因素。

Eur J Surg Oncol. 2018 Apr;44(4):429-435. doi: 10.1016/j.ejso.2017.12.007. Epub 2018 Jan 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验